Background
Multimorbidity, defined as the coexistence of at least two chronic diseases in an individual, is an increasing global public health concern mainly due to the aging population trend and urbanization [
1‐
3]. Multimorbidity causes huge burdens for individuals and society, as evidenced by increased rates of disability and mortality, serious psychological problems and high medical expenditures [
4‐
6]. Cardiometabolic multimorbidity (CM) is the most common and harmful pattern of multimorbidity, which refers to simultaneously suffering from more than one of coronary heart disease (CHD), stroke and type 2 diabetes [
4,
7]. It is reported that the medical history of CM was associated with a reduction in life expectancy of 15 years at the age of 60, which was almost twice as much as that for any single condition [
4]. Furthermore, participants with only one cardiometabolic disease and CM had a 1.4 and 1.9 times higher risk of mental stress than those without cardiometabolic disease, respectively [
8]. In spite of the increasing disease burden and alarming health damage, existing studies mainly focus on individual cardiometabolic diseases, and factors predicting CM are poorly understood.
Handgrip strength (HGS), an expedient and low-budget anthropological indicator, is conventionally considered to be an indicator of muscle strength and related to various adverse health events. Many studies have reported that HGS declines from midlife [
9,
10] and is highly correlated with new-onset cardiometabolic diseases and early mortality [
11‐
14]. For example, the Prospective Urban Rural Epidemiology (PURE) study holds that HGS was superior to systolic blood pressure in predicting cardiovascular diseases during a four-year follow-up [
11]. A study of middle-aged and elderly people in the USA and China reported that for every 0.05 decrease in the normalized grip strength (defined as grip strength divided by weight), the risk of type 2 diabetes increased by 0.49 times [
12]. Evidence from the Tromsø Study (
n = 6850; adults aged 50–80 years and followed up for 17 years) indicated that weaker HGS was associated with increased risks of all-cause mortality and cardiovascular mortality [
10]. Previous studies have also assessed the relationship between HGS and cardiometabolic diseases in the UK Biobank [
15‐
17]. Jirapitcha et al. provided evidence that low HGS was associated with a higher risk of incident type 2 diabetes in both men and women [
15]. Claire et al. found that HGS and usual walking pace had an additive effect to improve cardiovascular risk prediction [
16]. The analysis from a genetic risk perspective also demonstrated that the inverse correlation between HGS and CHD existed in different levels of genetic risk [
17]. Therefore, we speculate that HGS may be also an independent predictor for both new-onset CM cases and all-cause mortality events among patients with CM. However, few studies investigated the role of HGS in the whole progression to CM. Moreover, considering the huge reductions in life expectancy among patients with CM, estimating the association of HGS with all-cause mortality in patients with CM would be instructive for implementing tertiary prevention.
To address these limitations, we performed a prospective analysis of population-scale data from the UK Biobank. The objectives of this study are twofold: (1) to examine the association of HGS with the risk of CM in participants with none or only one cardiometabolic disease at recruitment and (2) to investigate the association of HGS with all-cause mortality risk in patients with CM at recruitment. In addition, as sex and age are the most common and important demographic characteristics in epidemiological studies and levels of handgrip strength differ greatly among different sexes and age levels [
18,
19], subgroup analyses by sex and age groups were performed to evaluate the robustness of the associations. These subgroup analyses by sex and age groups were specified a priori with the expectation of consistent findings.
Discussion
We examined the associations of HGS with morbidity and all-cause mortality of CM in a large national sample of UK adults. Our results revealed that lower HGS in individuals with none or a single cardiometabolic disease at baseline was positively associated with the risk of CM. In addition, a lower HGS was positively associated with all-cause mortality in people who experienced CM.
The current study extended previous studies by reporting a novel finding that lower HGS among participants free of any cardiometabolic disease was associated with a higher risk of CM. Many previous studies have found inverse correlations of HGS with risks of cardiovascular disease and type 2 diabetes [
18,
30‐
33], and muscle strengthening exercise for improving physical fitness, which is correlated with HGS, has been considered as a cost-effective prevention strategy for cardiovascular disease and type 2 diabetes [
34‐
36]. Using data from the UK Biobank, Carlos et al. reported a negative dose–response relationship between HGS and the risk of cardiovascular disease, and the HRs (95% CIs) were 1.15 (1.13–1.17) increased for women and 1.11 (1.10–1.12) increased for men per 5 kg lower HGS, respectively [
18]. A systematic review and meta-analysis conducted on 177,826 participants demonstrated that the relative risk (RR) of developing type 2 diabetes in the top tertile of HGS was decreased by 27% (16–37%), in comparison with the bottom tertile [
37]. In the current study, we observed not only the individual associations of HGS on cardiovascular disease and type 2 diabetes, but also an association of HGS with CM. Given this finding, screening and monitoring for CM may be instructive among “healthy” people with low HGS.
Our finding of the inverse correlation between HGS and new-onset CM in participants with preexisting type 2 diabetes was also in agreement with previous research [
31,
38,
39]. Carlos et al. reported that compared with the highest tertile of HGS in patients with type 2 diabetes, the HR (95% CI) value of the lowest tertile for new-onset cardiovascular disease was 1.87 (1.43–2.46) [
38]. Similarly, a retrospective clinical cohort study in Japan also demonstrated that HGS had an inverse association with the occurrence of cardiovascular disease in patients with type 2 diabetes at baseline [
31]. However, when the sex-stratified analysis in this study was performed, the association disappeared in both men and women, probably due to the relatively small sample sizes or short follow-up periods. Our prospective analyses of the UK Biobank also provide evidence for the association of HGS with new-onset cardiovascular disease in patients with diabetes.
Remarkably, as far as our information goes, the associations of HGS with the process of developing new-onset type 2 diabetes in patients with stroke or CHD has not been validated. However, the Emerging Risk Factors Collaboration indicated when compared to healthy individuals that the HR for all-cause mortality was about twice in participants with either stroke or myocardial infarction, whereas the risk was almost 4 times in participants with any two of stroke, type 2 diabetes and myocardial infarction [
4]. Therefore, our findings suggest that HGS could be an effective and practical indicator to monitor for CM not only in patients with type 2 diabetes but also in patients with stroke or CHD. Screening and interfering in patients who have low HGS with one cardiometabolic disease could be also important to prevent the development of CM.
To our knowledge, prior studies mainly focused on the predictive value of HGS on all-cause mortality among participants with none or one single cardiometabolic disease [
11,
32,
38,
40,
41]. Nevertheless, previous studies have already demonstrated that individuals with CM shared a shorter life expectancy than those with a single cardiometabolic disease [
4,
42]. Giving that HGS was demonstrated to be an independent predictor of all-cause mortality among patients with CM in our study, interfering in patients with low HGS who already experienced CM might be useful to prevent subsequent mortality.
The underlying mechanisms for the associations of HGS with CM have not been fully elucidated but may be explained from several aspects. First, low HGS is closely related to an early onset of obesity, and obesity increases the risk of dyslipidemia and systemic inflammation, which may be a common route for the development of diabetes, vascular diseases, and their serious complications [
43,
44]. Second, HGS is closely linked with undesirable cardiometabolic markers, such as glycosylated hemoglobin (HbA1c) and uric acid (UA) [
45,
46]. In addition to facilitating the diagnosis of diabetes, HbA1c is also used to explain the occurrence of CHD and ischemic stroke in many areas [
47]. Many epidemiological studies also showed that there was an association between elevated serum UA levels and cardiovascular disease. Intermediate processes may include the production of excessive UA, leading to increased oxidative stress, vasoconstriction, and vascular smooth muscle cell proliferation [
48,
49]. Third, a variety of myokines secreted during skeletal muscle exercise also have the effect of regulating the body’s metabolism. For example, functional deficiency of IL-6 may lead to atherosclerotic lipid conditions and insulin resistance [
50,
51].
Benefiting from the large sample size and long follow-up periods of the UK Biobank, we were able to investigate the role of baseline HGS in the whole progression to CM more thoroughly. Our study is the first to survey the relationship between baseline HGS and future CM among participants free of cardiometabolic diseases or those with stroke or CHD at recruitment. In addition, this study adds new knowledge that HGS could serve as an independent predictor of all-cause mortality among patients with CM at recruitment. However, we must be aware of some limitations in our study as well. First, as a population-based cohort study, the UK Biobank is not fully representative of the general population. However, a recent study has found the risk factor associations derived from the UK Biobank are basically in line with other representative cohorts [
52]. Second, although several common potential confounders associated with cardiovascular disease and diabetes had been adjusted at baseline, there might be other confounding factors that would affect the outcomes. Third, the survival bias may exist in this study since individuals with lower HGS are more likely to have died before the recruitment [
11,
18,
53], and the failure to include these individuals could result in the underestimation for the associations. Fourth, the HGS measurement may be more affected in patients with stroke as compared to others, as long-term disability is the most frequent complication after stroke [
54]. Fifth, subgroup analyses stratified by physical activity levels were post-hoc analyses which are less credible than pre-specified subgroup analyses [
55]. Sixth, the reverse association of HGS with the risk of CM from individuals with stroke at baseline was observed in the group of age < 60. The current findings also warrant further validation in patients with stroke with larger sample sizes. Last, although some studies suggested that using this approach of defining outcomes by ICD-10 codes might slightly underestimate the cases of common diseases, it has the advantage of being more in line with the actual health care system [
56,
57].
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.